Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

The Food and Drug Administration approval in December 2023 of the first CRISPR therapeutic, Casgevy to treat sickle cell, came 11 years after the discovery of the revolutionary gene-editing technology ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...

There is no “right” length of time to be in therapy. But for most people, there will come a time when therapy no longer feels necessary or progress has stalled. In most cases, the client will ...

such as antidepressants—as a treatment option and a complement to talk therapy. A session with a therapist can be a starting point for discussing potential benefits or concerns related to taking ...